Harrow, Inc. Finite-lived Intangible Assets Acquired
Harrow, Inc. (HROW) reported Finite-lived Intangible Assets Acquired of $2.63 million for the 9-month period ending 2015-09-30, per its 10-Q filed 2015-11-12.
Discontinued › Notes
us-gaap:FinitelivedIntangibleAssetsAcquired1 · last filed 2015-11-12
- Harrow, Inc. finite-lived intangible assets acquired for the quarter ending 2015-09-30 was $0.00.
- Harrow, Inc. finite-lived intangible assets acquired for the quarter ending 2015-06-30 was $4.00K.
- Harrow, Inc. finite-lived intangible assets acquired for the quarter ending 2015-03-31 was $2.63M.
- Harrow, Inc. finite-lived intangible assets acquired for the quarter ending 2014-12-31 was $0.00.
- Harrow, Inc. finite-lived intangible assets acquired for fiscal 2014 was $659.00K.
| Period end | Finite-lived Intangible Assets Acquired 3 month | Finite-lived Intangible Assets Acquired 6 month | Finite-lived Intangible Assets Acquired 9 month | Finite-lived Intangible Assets Acquired 12 month |
|---|---|---|---|---|
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $4.00K derived: sum of 2 quarters · filed 2015-11-12 | $2.63M 10-Q · filed 2015-11-12 | $2.63M derived: sum of 4 quarters · filed 2015-11-12 |
| 2015-06-30 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | $2.63M 10-Q · filed 2015-08-12 | $2.63M derived: sum of 3 quarters · filed 2015-08-12 | $2.63M derived: sum of 4 quarters · filed 2015-08-12 |
| 2015-03-31 | $2.63M 10-Q · filed 2015-05-13 | $2.63M derived: sum of 2 quarters · filed 2015-05-13 | $2.63M derived: sum of 3 quarters · filed 2015-05-13 | |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $0.00 derived: sum of 2 quarters · filed 2015-03-12 | $659.00K 10-K · filed 2015-03-12 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $659.00K 10-Q · filed 2014-11-12 | ||
| 2014-06-30 | $659.00K 10-Q · filed 2014-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |